JP2022516957A5 - - Google Patents

Info

Publication number
JP2022516957A5
JP2022516957A5 JP2021539682A JP2021539682A JP2022516957A5 JP 2022516957 A5 JP2022516957 A5 JP 2022516957A5 JP 2021539682 A JP2021539682 A JP 2021539682A JP 2021539682 A JP2021539682 A JP 2021539682A JP 2022516957 A5 JP2022516957 A5 JP 2022516957A5
Authority
JP
Japan
Prior art keywords
days
seq
per month
headache
overuse headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021539682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012790 external-priority patent/WO2020146535A1/en
Publication of JP2022516957A publication Critical patent/JP2022516957A/ja
Publication of JP2022516957A5 publication Critical patent/JP2022516957A5/ja
Priority to JP2024195562A priority Critical patent/JP2025032102A/ja
Withdrawn legal-status Critical Current

Links

JP2021539682A 2019-01-08 2020-01-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療 Withdrawn JP2022516957A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195562A JP2025032102A (ja) 2019-01-08 2024-11-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US62/789,828 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US62/840,967 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US62/841,585 2019-05-01
US201962872983P 2019-07-11 2019-07-11
US62/872,983 2019-07-11
PCT/US2020/012790 WO2020146535A1 (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195562A Division JP2025032102A (ja) 2019-01-08 2024-11-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療

Publications (2)

Publication Number Publication Date
JP2022516957A JP2022516957A (ja) 2022-03-03
JP2022516957A5 true JP2022516957A5 (https=) 2022-12-13

Family

ID=71404208

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539682A Withdrawn JP2022516957A (ja) 2019-01-08 2020-01-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療
JP2024195562A Pending JP2025032102A (ja) 2019-01-08 2024-11-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195562A Pending JP2025032102A (ja) 2019-01-08 2024-11-08 抗ｃｇｒｐ又は抗ｃｇｒｐ－ｒ抗体を用いた薬物乱用頭痛の治療

Country Status (24)

Country Link
US (2) US20200216525A1 (https=)
EP (1) EP3908607A4 (https=)
JP (2) JP2022516957A (https=)
KR (1) KR20210114002A (https=)
CN (2) CN119303074A (https=)
AU (1) AU2020207299A1 (https=)
BR (1) BR112020018044A2 (https=)
CA (1) CA3123292A1 (https=)
CL (1) CL2021001813A1 (https=)
CO (1) CO2021008665A2 (https=)
DO (1) DOP2021000145A (https=)
EC (1) ECSP21052193A (https=)
GE (2) GEAP202515689A (https=)
IL (1) IL284677A (https=)
JO (1) JOP20210166A1 (https=)
MA (1) MA54709A (https=)
MX (1) MX2021008268A (https=)
NI (1) NI202100063A (https=)
PE (1) PE20211708A1 (https=)
PH (1) PH12021551494A1 (https=)
SG (1) SG11202106878XA (https=)
TW (1) TW202030205A (https=)
UA (1) UA129265C2 (https=)
WO (1) WO2020146535A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
EP4570913A1 (en) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN118476508A (zh) * 2024-06-27 2024-08-13 中国人民解放军总医院第一医学中心 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
CN103585449B (zh) * 2013-10-23 2016-06-22 高丽丽 用于治疗偏头痛的中药组合物
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Similar Documents

Publication Publication Date Title
JP2022516957A5 (https=)
JP2022516956A5 (https=)
JP5835865B2 (ja) ロキソプロフェン含有医薬組成物
RS63260B1 (sr) Farmaceutske kompozicije koje obuhvataju meloksikam
JP2002538221A (ja) 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
CA2555688A1 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
JP5897804B2 (ja) ロキソプロフェン含有の医薬組成物
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
AU2025271432A1 (en) CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
Herrero et al. Antinociception and the new COX inhibitors: research approaches and clinical perspectives
TW201420133A (zh) 針對嚴重頭痛之普拉克索的經皮遞送
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
AU2006208945A1 (en) Analgesic compositions
AU2023202545A1 (en) Pharmaceutical compositions comprising meloxicam
US8598221B2 (en) Synergistic combination of analgesic compounds
Gershell et al. Making gains in pain.
TW202019484A (zh) 調節對鴉片、鴉片類或鴉片止痛劑之耐受性及治療急性及慢性疼痛之方法及組合
JP2011246433A (ja) ロキソプロフェン含有医薬組成物
Reisner-Keller Pharmacotherapeutics in the management of orofacial pain
US20090270400A1 (en) Painkilling association comprising a dihydroimidazopyrazine derivative
RU2021133433A (ru) Лечение головной боли с использованием антител к cgrp
Jansen Pharmacologic Treatment
JP6027916B2 (ja) ロキソプロフェン含有医薬組成物
Harvey The big goal of reducing fear-pain-stress in our clinical care.
JP2005532322A (ja) オピオイド鎮痛薬とｎｓａｉｄの相乗的な組合せ